Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(S 01): S16-S17
DOI: 10.4103/ijmpo.ijmpo_228_17
Original Article

Expected Hepatocarcinoma Cancer Rate Due to Escape Mutant among Local Population in Thailand: The Situation after the Implementation of Universal Hepatitis B Vaccination at Birth

Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok, Thailand
,
Viroj Wiwanitkit
Department of Tropical Medicine, Hainan Medical University, Haikou, Hainan, China
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Background: Chronic hepatitis B infection is an etiology of hepatocellular carcinoma. The high prevalence of hepatitis B can be seen in several regions including Indochina. In Thailand, a country in Indochina, according to the local public health policies, the universal hepatitis B vaccination is freely given to any infant at birth without charge. Despite the universal vaccination, the hepatitis B seropositive rate is still observed, and it can still be a cause of hepatocellular carcinoma among the hepatitis B carriers in the future. Methods: Here, the authors try to estimate the expected hepatocarcinoma cancer rate due to escape mutant among local population in Thailand, the situation after the implementation of universal hepatitis B vaccination at birth. Results: Based on the present study, the mutant escape contributes to only a few parts of overall estimated cancer cases in the situation that there is an implementation of universal hepatitis B vaccination at birth. Conclusion: Efficacy of theuniversal hepatitis B vaccination is not improved by specific management on escape mutants.

Keywords

Escape mutant - hepatitis B - Thailand - universal - vaccination


Publication History

Article published online:
24 May 2021

© 2019. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kew MC. Hepatocellular carcinoma: Epidemiology and risk factors. J Hepatocell Carcinoma 2014; 1: 115-25
    CrossrefPubMedGoogle Scholar
  • 2 Beasley RP. Rocks along the road to the control of HBV and HCC. Ann Epidemiol 2009; 19: 231-4
    CrossrefPubMedGoogle Scholar
  • 3 Yimnoi P, Posuwan N, Wanlapakorn N, Tangkijvanich P, Theamboonlers A, Vongpunsawad S. et al. A molecular epidemiological study of the hepatitis B virus in Thailand after 22 years of universal immunization. J Med Virol 2016; 88: 664-73
    CrossrefPubMedGoogle Scholar
  • 4 Vyas AK, Jindal A, Hissar S, Ramakrishna G, Trehanpati N. Immune balance in hepatitis B infection: Present and future therapies. Scand J Immunol 2017; 86: 4-14
    CrossrefPubMedGoogle Scholar
  • 5 Takano T, Tajiri H, Hosono S, Inui A, Murakami J, Ushijima K. et al. Natural history of chronic hepatitis B virus infection in children in Japan: A comparison of mother-to-child transmission with horizontal transmission. J Gastroenterol 2017; 52: 1041-50
    CrossrefPubMedGoogle Scholar
  • 6 Sa-Nguanmoo P, Tangkijvanich P, Tharmaphornpilas P, Rasdjarmrearnsook AO, Plianpanich S, Thawornsuk N. et al. Molecular analysis of hepatitis B virus associated with vaccine failure in infants and mothers: A case-control study in Thailand. J Med Virol 2012; 84: 1177-85
    CrossrefPubMedGoogle Scholar
  • 7 Chinchai T, Chirathaworn C, Praianantathavorn K, Theamboonlers A, Hutagalung Y, Bock PH. et al. Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization. Viral Immunol 2009; 22: 125-30
    CrossrefPubMedGoogle Scholar